Dowling & Yahnke’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $992K | Sell |
3,717
-401
| -10% | -$85.2K | 0.05% | 223 |
|
|
2022
Q2 | $840K | Sell |
4,118
-924
| -18% | -$189K | 0.04% | 230 |
|
|
2022
Q1 | $1.06M | Sell |
5,042
-963
| -16% | -$209K | 0.05% | 224 |
|
|
2021
Q4 | $1.44M | Sell |
6,005
-559
| -9% | -$144K | 0.07% | 196 |
|
|
2021
Q3 | $1.86M | Sell |
6,564
-290
| -4% | -$95K | 0.1% | 171 |
|
|
2021
Q2 | $2.37M | Sell |
6,854
-51
| -0.7% | -$15.4K | 0.14% | 156 |
|
|
2021
Q1 | $1.93M | Sell |
6,905
-170
| -2% | -$45.8K | 0.13% | 157 |
|
|
2020
Q4 | $1.73M | Sell |
7,075
-222
| -3% | -$57.3K | 0.12% | 158 |
|
|
2020
Q3 | $2.07M | Sell |
7,297
-110
| -1% | -$30.7K | 0.17% | 139 |
|
|
2020
Q2 | $1.98M | Sell |
7,407
-75
| -1% | -$22.5K | 0.17% | 139 |
|
|
2020
Q1 | $2.37M | Buy |
7,482
+97
| +1% | +$29.4K | 0.23% | 118 |
|
|
2019
Q4 | $2.19M | Buy |
7,385
+338
| +5% | +$93.8K | 0.17% | 138 |
|
|
2019
Q3 | $1.64M | Sell |
7,047
-131
| -2% | -$30.5K | 0.14% | 160 |
|
|
2019
Q2 | $1.68M | Sell |
7,178
-1,413
| -16% | -$326K | 0.14% | 156 |
|
|
2019
Q1 | $2.03M | Buy |
8,591
+592
| +7% | +$186K | 0.2% | 122 |
|
|
2018
Q4 | $2.67M | Buy |
7,999
+97
| +1% | +$31K | 0.28% | 98 |
|
|
2018
Q3 | $2.79M | Buy |
7,902
+3
| +0% | +$1.03K | 0.24% | 113 |
|
|
2018
Q2 | $2.29M | Buy |
7,899
+406
| +5% | +$114K | 0.21% | 128 |
|
|
2018
Q1 | $2.05M | Buy |
7,493
+178
| +2% | +$55.3K | 0.19% | 137 |
|
|
2017
Q4 | $2.33M | Buy |
7,315
+133
| +2% | +$42.7K | 0.21% | 129 |
|
|
2017
Q3 | $2.25M | Buy |
7,182
+347
| +5% | +$103K | 0.23% | 123 |
|
|
2017
Q2 | $1.85M | Sell |
6,835
-67
| -1% | -$17.7K | 0.2% | 136 |
|
|
2017
Q1 | $1.89M | Buy |
6,902
+273
| +4% | +$77.2K | 0.2% | 136 |
|
|
2016
Q4 | $1.88M | Buy |
6,629
+168
| +3% | +$49.8K | 0.21% | 126 |
|
|
2016
Q3 | $2.02M | Buy |
6,461
+450
| +7% | +$133K | 0.24% | 122 |
|
|
2016
Q2 | $1.45M | Buy |
6,011
+850
| +16% | +$224K | 0.17% | 140 |
|
|
2016
Q1 | $1.34M | Buy |
5,161
+361
| +8% | +$95.4K | 0.17% | 143 |
|
|
2015
Q4 | $1.47M | Buy |
4,800
+196
| +4% | +$56.3K | 0.18% | 131 |
|
|
2015
Q3 | $1.34M | Buy |
4,604
+1,336
| +41% | +$441K | 0.18% | 134 |
|
|
2015
Q2 | $1.32M | Buy |
3,268
+195
| +6% | +$78.3K | 0.17% | 137 |
|
|
2015
Q1 | $1.3M | Buy |
3,073
+4
| +0.1% | +$1.58K | 0.16% | 137 |
|
|
2014
Q4 | $1.04M | Buy |
3,069
+220
| +8% | +$71.2K | 0.13% | 150 |
|
|
2014
Q3 | $942K | Buy |
2,849
+92
| +3% | +$30.3K | 0.12% | 149 |
|
|
2014
Q2 | $869K | Buy |
2,757
+138
| +5% | +$41.5K | 0.11% | 157 |
|
|
2014
Q1 | $801K | Buy |
2,619
+234
| +10% | +$74.3K | 0.11% | 159 |
|
|
2013
Q4 | $667K | Sell |
2,385
-75
| -3% | -$19.4K | 0.09% | 168 |
|
|
2013
Q3 | $592K | Buy |
2,460
+176
| +8% | +$39.4K | 0.09% | 168 |
|
|
2013
Q2 | $492K | Buy |
+2,284
| New | +$488K | 0.08% | 172 |
|
Other funds holding BIIB
Dowling & Yahnke's BIIB Position: Q3 2022 in Review
Dowling & Yahnke reduced its Biogen (BIIB) stake by 9.7% in Q3 2022, selling an estimated $85.2K and leaving 3,717 shares worth $992K. The position accounts for 0.05% of the portfolio, ranked #223.
Dowling & Yahnke first reported a position in BIIB in Q2 2013 and has held it in 38 quarters since. The position peaked at $2.79M in Q3 2018. 987 funds tracked by Wall St. Rank hold BIIB as of Q3 2022.
- Dowling & Yahnke held 3,717 shares of Biogen worth $992K as of Q3 2022.
- Dowling & Yahnke sold 401 Biogen shares in Q3 2022, an estimated $85.2K.
- Biogen made up 0.05% of Dowling & Yahnke's portfolio in Q3 2022, its #223 holding.
- Dowling & Yahnke first reported a position in Biogen in Q2 2013 and has held it in 38 quarters since.
- Dowling & Yahnke's Biogen position peaked at $2.79M in Q3 2018.
- 987 funds tracked by Wall St. Rank held Biogen as of Q3 2022.
Based on Dowling & Yahnke's 13F filing for Q3 2022, filed 3 Nov 2022.